GSK plc files 2024 Annual Report on Form 20-F
GSK plc has submitted its 2024 annual report to the SEC. The filing provides comprehensive details on the company's financial performance and business operations for the fiscal year ended December 31, 2024.
GSK plc, a global biopharma company, has officially filed its annual report on Form 20-F with the U.S. Securities and Exchange Commission (SEC).
The document, submitted on March 3, 2025, covers the company's performance for the fiscal year ending December 31, 2024. As a company incorporated in England and listed on the New York Stock Exchange, GSK adheres to SEC reporting requirements for public companies.
The Form 20-F provides an overview of GSK's business, financial condition, risk factors, and capital structure. It also details the company's research and development activities, offering insights into its ongoing efforts in drug discovery and development. This annual filing is crucial for investors and stakeholders to assess the company's progress and strategic direction.
GSK confirmed its compliance with filing obligations, indicating it has submitted all required reports and interactive data files over the past 12 months. The company prepares its financial statements in accordance with International Financial Reporting Standards (IFRS) as issued by the IASB, and also references U.S. GAAP.